Logo image of TARS

TARSUS PHARMACEUTICALS INC (TARS) Stock Fundamental Analysis

NASDAQ:TARS - US87650L1035 - Common Stock

57.32 USD
+0.07 (+0.12%)
Last: 8/25/2025, 11:58:56 AM
Fundamental Rating

4

Taking everything into account, TARS scores 4 out of 10 in our fundamental rating. TARS was compared to 193 industry peers in the Pharmaceuticals industry. TARS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TARS is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TARS had negative earnings in the past year.
TARS had a negative operating cash flow in the past year.
In the past 5 years TARS always reported negative net income.
In the past 5 years TARS reported 4 times negative operating cash flow.
TARS Yearly Net Income VS EBIT VS OCF VS FCFTARS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

The Return On Assets of TARS (-18.58%) is better than 61.66% of its industry peers.
TARS has a Return On Equity of -27.66%. This is in the better half of the industry: TARS outperforms 61.14% of its industry peers.
Industry RankSector Rank
ROA -18.58%
ROE -27.66%
ROIC N/A
ROA(3y)-36.36%
ROA(5y)-26.48%
ROE(3y)-50.88%
ROE(5y)-35.42%
ROIC(3y)N/A
ROIC(5y)N/A
TARS Yearly ROA, ROE, ROICTARS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

TARS has a Gross Margin of 93.36%. This is amongst the best in the industry. TARS outperforms 96.37% of its industry peers.
TARS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TARS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5YN/A
TARS Yearly Profit, Operating, Gross MarginsTARS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

TARS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TARS has more shares outstanding
Compared to 5 years ago, TARS has more shares outstanding
The debt/assets ratio for TARS is higher compared to a year ago.
TARS Yearly Shares OutstandingTARS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TARS Yearly Total Debt VS Total AssetsTARS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

TARS has an Altman-Z score of 8.66. This indicates that TARS is financially healthy and has little risk of bankruptcy at the moment.
TARS has a better Altman-Z score (8.66) than 87.05% of its industry peers.
TARS has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
TARS has a Debt to Equity ratio (0.22) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 8.66
ROIC/WACCN/A
WACC10.06%
TARS Yearly LT Debt VS Equity VS FCFTARS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TARS has a Current Ratio of 5.26. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.26, TARS is in the better half of the industry, outperforming 72.54% of the companies in the same industry.
A Quick Ratio of 5.21 indicates that TARS has no problem at all paying its short term obligations.
TARS's Quick ratio of 5.21 is fine compared to the rest of the industry. TARS outperforms 73.58% of its industry peers.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 5.21
TARS Yearly Current Assets VS Current LiabilitesTARS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

TARS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.99%, which is quite impressive.
Looking at the last year, TARS shows a very strong growth in Revenue. The Revenue has grown by 254.46%.
The Revenue has been growing by 47.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)47.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)254.46%
Revenue growth 3Y47.48%
Revenue growth 5YN/A
Sales Q2Q%151.54%

3.2 Future

TARS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.66% yearly.
Based on estimates for the next years, TARS will show a very strong growth in Revenue. The Revenue will grow by 42.29% on average per year.
EPS Next Y54.78%
EPS Next 2Y59.54%
EPS Next 3Y50.28%
EPS Next 5Y18.66%
Revenue Next Year34040.4%
Revenue Next 2Y86.5%
Revenue Next 3Y67.47%
Revenue Next 5Y42.29%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
TARS Yearly Revenue VS EstimatesTARS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20B 40B 60B
TARS Yearly EPS VS EstimatesTARS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TARS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 33.91 indicates a quite expensive valuation of TARS.
Based on the Price/Forward Earnings ratio, TARS is valued a bit cheaper than 69.95% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of TARS to the average of the S&P500 Index (22.81), we can say TARS is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 33.91
TARS Price Earnings VS Forward Price EarningsTARS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TARS Per share dataTARS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

TARS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TARS's earnings are expected to grow with 50.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.54%
EPS Next 3Y50.28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TARS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TARSUS PHARMACEUTICALS INC

NASDAQ:TARS (8/25/2025, 11:58:56 AM)

57.32

+0.07 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners103.25%
Inst Owner Change5.27%
Ins Owners3.35%
Ins Owner Change1.13%
Market Cap2.42B
Analysts87.14
Price Target75.19 (31.18%)
Short Float %20.75%
Short Ratio12.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.83%
Min EPS beat(2)-17.77%
Max EPS beat(2)14.11%
EPS beat(4)3
Avg EPS beat(4)13.91%
Min EPS beat(4)-17.77%
Max EPS beat(4)38.51%
EPS beat(8)7
Avg EPS beat(8)11.74%
EPS beat(12)10
Avg EPS beat(12)11.83%
EPS beat(16)12
Avg EPS beat(16)8.05%
Revenue beat(2)2
Avg Revenue beat(2)5.58%
Min Revenue beat(2)5.19%
Max Revenue beat(2)5.98%
Revenue beat(4)4
Avg Revenue beat(4)7.85%
Min Revenue beat(4)5.19%
Max Revenue beat(4)11.62%
Revenue beat(8)8
Avg Revenue beat(8)74.75%
Revenue beat(12)8
Avg Revenue beat(12)31.2%
Revenue beat(16)9
Avg Revenue beat(16)8.87%
PT rev (1m)6.17%
PT rev (3m)4.03%
EPS NQ rev (1m)-26.18%
EPS NQ rev (3m)16.55%
EPS NY rev (1m)-15.86%
EPS NY rev (3m)-13.45%
Revenue NQ rev (1m)8%
Revenue NQ rev (3m)26.13%
Revenue NY rev (1m)14823.3%
Revenue NY rev (3m)15051%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 33.91
P/S 8.19
P/FCF N/A
P/OCF N/A
P/B 7.27
P/tB 7.45
EV/EBITDA N/A
EPS(TTM)-2.33
EYN/A
EPS(NY)1.69
Fwd EY2.95%
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-1.92
OCFYN/A
SpS7
BVpS7.88
TBVpS7.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.58%
ROE -27.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.36%
FCFM N/A
ROA(3y)-36.36%
ROA(5y)-26.48%
ROE(3y)-50.88%
ROE(5y)-35.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5YN/A
F-Score5
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 426.34%
Cap/Sales 2.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 5.21
Altman-Z 8.66
F-Score5
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)439.33%
Cap/Depr(5y)393.66%
Cap/Sales(3y)12.37%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y54.78%
EPS Next 2Y59.54%
EPS Next 3Y50.28%
EPS Next 5Y18.66%
Revenue 1Y (TTM)254.46%
Revenue growth 3Y47.48%
Revenue growth 5YN/A
Sales Q2Q%151.54%
Revenue Next Year34040.4%
Revenue Next 2Y86.5%
Revenue Next 3Y67.47%
Revenue Next 5Y42.29%
EBIT growth 1Y37.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.54%
EBIT Next 3Y55.7%
EBIT Next 5Y22.13%
FCF growth 1Y-14.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.43%
OCF growth 3YN/A
OCF growth 5YN/A